PT-141

What Is PT-141 (Bremelanotide)?

Dragon Pharma PT-141, known generically as Bremelanotide, is a synthetic cyclic heptapeptide and melanocortin receptor agonist derived from Melanotan II. It is one of the most extensively researched peptides in the field of sexual health and arousal science.

Unlike conventional treatments for sexual dysfunction that target blood flow — such as PDE-5 inhibitors like Viagra or Cialis — PT-141 operates through an entirely different pathway. It acts directly on the central nervous system, binding to MC3R and MC4R receptors in the hypothalamus to stimulate the brain's natural arousal and desire circuits.

In 2019, Bremelanotide became the first peptide of its kind to receive FDA approval, marketed under the brand name Vyleesi® for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. Its unique mechanism and clinical validation have made it a reference compound in peptide sexual health research.

Dragon Pharma PT-141 is manufactured to research-grade standards, providing investigators with a reliable and consistent reference compound for laboratory work involving melanocortin receptor signaling.

How PT-141 Works: Mechanism of Action

PT-141's mechanism is what sets it apart from every other compound in its category. Rather than acting peripherally on the vascular system, it targets the neurological root of sexual desire.

Central Nervous System Activation

PT-141 binds primarily to MC3R and MC4R receptors located in the hypothalamus — the brain region responsible for regulating arousal, motivation, and reproductive behavior. This binding triggers a downstream cascade of neural and hormonal responses associated with sexual interest and readiness.

Dopamine Pathway Stimulation

By activating melanocortin receptors, PT-141 enhances dopamine signaling within the brain's reward and motivation networks. Dopamine is the primary neurotransmitter involved in desire, drive, and anticipatory pleasure — making this mechanism highly relevant to libido research.

Independence from Nitric Oxide Pathways

Unlike PDE-5 inhibitors, PT-141 does not rely on the nitric oxide–cGMP pathway to produce its effects. Research suggests this makes it potentially useful in cases where traditional ED medications are insufficient, since it bypasses the vascular pathway entirely.

Onset and Duration

Clinical observations note that effects from subcutaneous administration are typically observable within 30 to 60 minutes, with activity persisting for several hours depending on dose and individual sensitivity.

Research Applications of PT-141

PT-141 (Bremelanotide) is studied across multiple domains of reproductive and sexual health science:

Female Sexual Dysfunction Research

PT-141 is the active ingredient in FDA-approved Vyleesi®, indicated for hypoactive sexual desire disorder (HSDD) in premenopausal women. Phase 3 RECONNECT trials demonstrated statistically significant improvements in sexual desire scores and reductions in distress compared to placebo, establishing its efficacy profile in this population.

Male Sexual Dysfunction Research

Preclinical and clinical research has explored PT-141 in male subjects. Studies suggest that MC4R activation may upregulate the production of vasodilators within cavernosal tissue, supporting erectile function through a mechanism distinct from PDE-5 inhibition. This makes it of particular research interest for subjects who do not respond adequately to standard ED treatments.

Melanocortin Receptor Signaling Studies

Beyond sexual function, PT-141's selective binding profile at MC3R and MC4R — with comparatively reduced MC1R activity relative to its parent compound Melanotan II — makes it a valuable tool for researchers investigating central melanocortin signaling pathways, energy homeostasis, and neuroendocrine regulation.

Comparative Peptide Research

PT-141 is frequently used as a reference comparator in studies involving:

• Melanotan II (MT-2)
• Alpha-melanocyte stimulating hormone (α-MSH)
• Other melanocortin receptor agonists and antagonists

PT-141 vs. Other Sexual Health Compounds

Understanding how PT-141 differs from other commonly studied compounds is central to designing meaningful research protocols.

PT-141 vs. PDE-5 Inhibitors (Sildenafil / Tadalafil)

Feature	PT-141	PDE-5 Inhibitors
Primary target	Central nervous system	Vascular system
Mechanism	MC3R / MC4R agonism	Nitric oxide / cGMP pathway
Effect on desire	Direct stimulation	Indirect (performance-focused)
Hormone dependence	None	None
Applicability	Low desire + dysfunction	Primarily erectile dysfunction

The two compound classes are mechanistically complementary. Some research protocols have explored combining a centrally acting melanocortin agonist with a peripherally acting PDE-5 inhibitor to address both desire and physical performance dimensions simultaneously.

PT-141 vs. Melanotan II (MT-2)

PT-141 emerged from Melanotan II research when scientists observed that MT-2 had pronounced effects on sexual arousal during tanning peptide studies. PT-141 was developed as a refined analog with:

• Stronger selectivity for MC3R/MC4R over MC1R
• Reduced tanning/pigmentation activity
• A more targeted arousal-focused pharmacological profile

PT-141 vs. Testosterone (TRT)

Testosterone therapy works systemically by normalizing androgen levels, which can broadly improve energy, mood, and libido over time. PT-141 acts independently of hormone status, making it relevant for on-demand research scenarios where desire circuits are being studied directly, regardless of baseline testosterone levels.

PT-141 Dosage Protocols in Research

The following information reflects protocols documented in clinical literature and research community reports. All dosing references are for research context only.

FDA-Approved Protocol (Vyleesi®)

• **Dose:** 1.75 mg via subcutaneous auto-injector
• **Timing:** Approximately 45 minutes before anticipated sexual activity
• **Frequency:** Maximum 1 dose per 24 hours; up to 8 doses per month

Research-Grade Subcutaneous Protocol

• **Typical range:** 250 mcg – 2 mg per administration
• **Onset:** Effects typically observed within 30–60 minutes
• **Duration:** Several hours, dose-dependent
• **Starting point:** Many research protocols initiate at 250–500 mcg to assess response before titrating upward
• **Frequency:** On-demand, not intended for daily continuous use

Reconstitution (Standard Research Practice)

• Reconstitute lyophilized powder in bacteriostatic water (minimum 100 µg/mL)
• Store reconstituted solution at 2–8°C for short-term use (up to 7 days)
• For extended storage, keep below -18°C; avoid freeze-thaw cycles

PT-141 Side Effect Profile

PT-141's safety profile is among the best documented of any research peptide, owing to its FDA approval pathway. The following adverse events have been recorded in clinical trials:

Side Effect	Frequency	Notes
Nausea	Up to 40%	Most common; typically transient and dose-dependent
Flushing	Common	Related to CNS and mild vascular activation
Headache	Common	Usually self-resolving
Blood pressure increase	Transient	Accompanied by mild heart rate decrease; caution in CV disease
Injection site reactions	With SC use	Redness, itching, localized irritation
Skin pigmentation changes	Less common	Linked to residual MC1R activity from melanocortin origin

Note: PT-141 is contraindicated in individuals with uncontrolled hypertension or significant cardiovascular disease due to its transient hemodynamic effects.

Dragon Pharma PT-141 — Product Specifications

Parameter	Detail
Purity	≥99% (HPLC verified)
Form	Lyophilized powder
Vial size	10 mg
Peptide sequence	Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH
Structure	Cyclic heptapeptide (lactam bridge)
Short-term storage	2–8°C (up to 7 days reconstituted)
Long-term storage	Below -20°C (lyophilized)
Usage	Research purposes only

Dragon Pharma products are manufactured under rigorous quality control standards, with every batch verified for purity and peptide integrity before release.

Frequently Asked Questions About PT-141

What makes PT-141 different from Viagra?

Viagra (sildenafil) improves blood flow to genital tissue via the nitric oxide–cGMP pathway and addresses the physical mechanics of erection. PT-141 works in the brain, stimulating melanocortin receptors to directly influence sexual desire and arousal, independently of blood flow. The two mechanisms are complementary rather than competitive.

Can PT-141 be used by both men and women?

Yes. PT-141 is FDA-approved specifically for premenopausal women with HSDD (as Vyleesi®). Clinical research and community reports also document its use in male subjects, particularly those studying desire-related dysfunction that does not respond adequately to PDE-5 inhibitors.

How long does PT-141 take to work?

Based on clinical data, subcutaneous administration typically produces noticeable effects within 30–60 minutes, with activity lasting several hours depending on dose and individual response.

Does PT-141 cause tanning or skin darkening?

Some users of PT-141 report mild pigmentation changes, as the compound retains partial MC1R activity from its Melanotan II origin. This effect is significantly less pronounced than with MT-2, owing to PT-141's refined receptor selectivity profile.

What is the difference between PT-141 and Melanotan II?

Melanotan II (MT-2) is a broad-acting melanocortin agonist that strongly activates MC1R (responsible for skin tanning) in addition to MC3R/MC4R. PT-141 (Bremelanotide) was developed as a derivative with reduced MC1R activity and stronger emphasis on the MC3R/MC4R pathways that govern arousal, resulting in a more targeted sexual health research profile with less pigmentation activity.

Is PT-141 safe for long-term use?

Long-term safety data is limited. Research protocols involving extended use should be designed accordingly, with appropriate monitoring of hemodynamic parameters.

What is the PT-141 molecular weight?

PT-141 (Bremelanotide) has a molecular weight of 1025.18 g/mol and a molecular formula of C50H68N14O10. Its CAS number is 189691-06-3.

Related Dragon Pharma Peptides

• **Melanotan II (MT-2)** — Broader-spectrum melanocortin agonist; tanning + arousal research
• **BPC-157** — Peptide studied for tissue repair and gut health
• **TB-500** — Thymosin beta-4 analog; recovery and regeneration research
• **CJC-1295 / Ipamorelin** — Growth hormone secretagogue research stack
• **Selank / Semax** — Nootropic peptide research

Dragon Pharma PT-141 is provided for research and laboratory use only. All information on this page is for educational purposes. This product is not intended to diagnose, treat, cure, or prevent any disease. Not for human or animal consumption.